Therapeutic  ||| S:0 E:12 ||| JJ
cancer  ||| S:12 E:19 ||| NN
vaccines  ||| S:19 E:28 ||| NNS
in  ||| S:28 E:31 ||| IN
cervical  ||| S:31 E:40 ||| JJ
cancer ||| S:40 E:46 ||| NN
:  ||| S:46 E:48 ||| :
phase  ||| S:48 E:54 ||| VB
I  ||| S:54 E:56 ||| PRP
study  ||| S:56 E:62 ||| VBP
of  ||| S:62 E:65 ||| IN
Lovaxin-C  ||| S:65 E:75 ||| NNP
Producing  ||| S:75 E:85 ||| NNP
effective  ||| S:85 E:95 ||| JJ
therapeutic  ||| S:95 E:107 ||| JJ
vaccines  ||| S:107 E:116 ||| NN
has  ||| S:116 E:120 ||| VBZ
proved  ||| S:120 E:127 ||| VBN
much  ||| S:127 E:132 ||| RB
more  ||| S:132 E:137 ||| RBR
difficult  ||| S:137 E:147 ||| JJ
and  ||| S:147 E:151 ||| CC
challenging  ||| S:151 E:163 ||| VBG
than  ||| S:163 E:168 ||| IN
developing  ||| S:168 E:179 ||| VBG
cancer  ||| S:179 E:186 ||| NN
preventive  ||| S:186 E:197 ||| NN
vaccines ||| S:197 E:205 ||| NNS
.  ||| S:205 E:207 ||| .
Despite  ||| S:207 E:215 ||| IN
huge  ||| S:215 E:220 ||| JJ
research  ||| S:220 E:229 ||| NN
in  ||| S:229 E:232 ||| IN
the  ||| S:232 E:236 ||| DT
area  ||| S:236 E:241 ||| NN
of  ||| S:241 E:244 ||| IN
cancer  ||| S:244 E:251 ||| NN
immunology ||| S:251 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
FDA ||| S:263 E:266 ||| NNP
/ ||| S:266 E:267 ||| NNP
EMEA  ||| S:267 E:272 ||| NNP
have  ||| S:272 E:277 ||| VBP
not  ||| S:277 E:281 ||| RB
approved  ||| S:281 E:290 ||| VBD
any  ||| S:290 E:294 ||| DT
type  ||| S:294 E:299 ||| NN
of  ||| S:299 E:302 ||| IN
cancer  ||| S:302 E:309 ||| NN
treatment  ||| S:309 E:319 ||| NN
vaccine  ||| S:319 E:327 ||| NN
so  ||| S:327 E:330 ||| RB
far ||| S:330 E:333 ||| RB
.  ||| S:333 E:335 ||| .
More  ||| S:335 E:340 ||| RBR
than  ||| S:340 E:345 ||| IN
99 ||| S:345 E:347 ||| CD
%  ||| S:347 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
cervical  ||| S:352 E:361 ||| JJ
cancers  ||| S:361 E:369 ||| NNS
have  ||| S:369 E:374 ||| VBP
detectable  ||| S:374 E:385 ||| JJ
amounts  ||| S:385 E:393 ||| NNS
of  ||| S:393 E:396 ||| IN
human  ||| S:396 E:402 ||| JJ
papillomavirus  ||| S:402 E:417 ||| NNS
( ||| S:417 E:418 ||| -LRB-
HPV ||| S:418 E:421 ||| NNP
)  ||| S:421 E:423 ||| -RRB-
DNA ||| S:423 E:426 ||| NNP
.  ||| S:426 E:428 ||| .
Integration  ||| S:428 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
high-risk  ||| S:443 E:453 ||| JJ
HPV  ||| S:453 E:457 ||| NN
into  ||| S:457 E:462 ||| IN
the  ||| S:462 E:466 ||| DT
host  ||| S:466 E:471 ||| NN
cell  ||| S:471 E:476 ||| NN
genome  ||| S:476 E:483 ||| NN
is  ||| S:483 E:486 ||| VBZ
followed  ||| S:486 E:495 ||| VBN
by  ||| S:495 E:498 ||| IN
continual  ||| S:498 E:508 ||| JJ
expression  ||| S:508 E:519 ||| NN
of  ||| S:519 E:522 ||| IN
HPV  ||| S:522 E:526 ||| NNP
E6  ||| S:526 E:529 ||| NNP
and  ||| S:529 E:533 ||| CC
E7  ||| S:533 E:536 ||| CD
oncoproteins ||| S:536 E:548 ||| NN
,  ||| S:548 E:550 ||| ,
making  ||| S:550 E:557 ||| VBG
them  ||| S:557 E:562 ||| PRP
excellent  ||| S:562 E:572 ||| JJ
targets  ||| S:572 E:580 ||| NNS
for  ||| S:580 E:584 ||| IN
developing  ||| S:584 E:595 ||| VBG
vaccines  ||| S:595 E:604 ||| NNS
which  ||| S:604 E:610 ||| WDT
could  ||| S:610 E:616 ||| MD
be  ||| S:616 E:619 ||| VB
used  ||| S:619 E:624 ||| VBN
in  ||| S:624 E:627 ||| IN
high  ||| S:627 E:632 ||| JJ
grade  ||| S:632 E:638 ||| NN
precancerous  ||| S:638 E:651 ||| NNS
( ||| S:651 E:652 ||| -LRB-
CIN ||| S:652 E:655 ||| NNP
)  ||| S:655 E:657 ||| -RRB-
lesions  ||| S:657 E:665 ||| NNS
or  ||| S:665 E:668 ||| CC
invasive  ||| S:668 E:677 ||| JJ
cancer  ||| S:677 E:684 ||| NN
or  ||| S:684 E:687 ||| CC
in  ||| S:687 E:690 ||| IN
the  ||| S:690 E:694 ||| DT
prevention  ||| S:694 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
cancer  ||| S:708 E:715 ||| NN
recurrence ||| S:715 E:725 ||| NN
.  ||| S:725 E:727 ||| .
Therapeutic  ||| S:727 E:739 ||| JJ
cervical  ||| S:739 E:748 ||| JJ
cancer  ||| S:748 E:755 ||| NN
vaccines  ||| S:755 E:764 ||| NNS
have  ||| S:764 E:769 ||| VBP
been  ||| S:769 E:774 ||| VBN
extensively  ||| S:774 E:786 ||| RB
studied ||| S:786 E:793 ||| VBN
.  ||| S:793 E:795 ||| .
Strategies  ||| S:795 E:806 ||| NNS
used  ||| S:806 E:811 ||| VBN
were  ||| S:811 E:816 ||| VBD
vaccination  ||| S:816 E:828 ||| VBN
with  ||| S:828 E:833 ||| IN
HPV  ||| S:833 E:837 ||| NNP
peptides  ||| S:837 E:846 ||| NN
or  ||| S:846 E:849 ||| CC
proteins ||| S:849 E:857 ||| NNS
,  ||| S:857 E:859 ||| ,
alone  ||| S:859 E:865 ||| RB
or  ||| S:865 E:868 ||| CC
in  ||| S:868 E:871 ||| IN
pulsed  ||| S:871 E:878 ||| JJ
dendritic  ||| S:878 E:888 ||| JJ
cells ||| S:888 E:893 ||| NNS
,  ||| S:893 E:895 ||| ,
DNA  ||| S:895 E:899 ||| NNP
vaccines ||| S:899 E:907 ||| NNS
,  ||| S:907 E:909 ||| ,
virus-like  ||| S:909 E:920 ||| JJ
particles  ||| S:920 E:930 ||| NN
or  ||| S:930 E:933 ||| CC
viral  ||| S:933 E:939 ||| JJ
and  ||| S:939 E:943 ||| CC
bacterial  ||| S:943 E:953 ||| JJ
vectors ||| S:953 E:960 ||| NN
.  ||| S:960 E:962 ||| .
Lovaxin-C  ||| S:962 E:972 ||| NNP
is  ||| S:972 E:975 ||| VBZ
a  ||| S:975 E:977 ||| DT
recombinant  ||| S:977 E:989 ||| JJ
live-attenuated  ||| S:989 E:1005 ||| JJ
Listeria  ||| S:1005 E:1014 ||| JJ
monocytogenes  ||| S:1014 E:1028 ||| NNS
( ||| S:1028 E:1029 ||| -LRB-
Lm ||| S:1029 E:1031 ||| NNP
)  ||| S:1031 E:1033 ||| -RRB-
that  ||| S:1033 E:1038 ||| WDT
secretes  ||| S:1038 E:1047 ||| VBZ
the  ||| S:1047 E:1051 ||| DT
antigen  ||| S:1051 E:1059 ||| JJ
HPV-16  ||| S:1059 E:1066 ||| CD
E7  ||| S:1066 E:1069 ||| CD
fused  ||| S:1069 E:1075 ||| NN
to  ||| S:1075 E:1078 ||| TO
a  ||| S:1078 E:1080 ||| DT
non-hemolytic  ||| S:1080 E:1094 ||| JJ
listeriolysin  ||| S:1094 E:1108 ||| JJ
O  ||| S:1108 E:1110 ||| NNP
protein ||| S:1110 E:1117 ||| NN
.  ||| S:1117 E:1119 ||| .
In  ||| S:1119 E:1122 ||| IN
a  ||| S:1122 E:1124 ||| DT
phase  ||| S:1124 E:1130 ||| NN
I  ||| S:1130 E:1132 ||| PRP
study  ||| S:1132 E:1138 ||| VBP
Lovaxin-C  ||| S:1138 E:1148 ||| NNP
was  ||| S:1148 E:1152 ||| VBD
administered  ||| S:1152 E:1165 ||| VBN
to  ||| S:1165 E:1168 ||| TO
advanced  ||| S:1168 E:1177 ||| JJ
cervical  ||| S:1177 E:1186 ||| JJ
cancer  ||| S:1186 E:1193 ||| NN
patients  ||| S:1193 E:1202 ||| NNS
refractory  ||| S:1202 E:1213 ||| VBP
to  ||| S:1213 E:1216 ||| TO
existing  ||| S:1216 E:1225 ||| VBG
therapies ||| S:1225 E:1234 ||| NNS
.  ||| S:1234 E:1236 ||| .
The  ||| S:1236 E:1240 ||| DT
dose-limiting  ||| S:1240 E:1254 ||| JJ
toxicity  ||| S:1254 E:1263 ||| NN
was  ||| S:1263 E:1267 ||| VBD
hypotension  ||| S:1267 E:1279 ||| JJ
and  ||| S:1279 E:1283 ||| CC
flue-like  ||| S:1283 E:1293 ||| JJ
syndrome ||| S:1293 E:1301 ||| NN
.  ||| S:1301 E:1303 ||| .
There  ||| S:1303 E:1309 ||| EX
were  ||| S:1309 E:1314 ||| VBD
no  ||| S:1314 E:1317 ||| DT
serious  ||| S:1317 E:1325 ||| JJ
adverse  ||| S:1325 E:1333 ||| JJ
events ||| S:1333 E:1339 ||| NNS
.  ||| S:1339 E:1341 ||| .
Specific  ||| S:1341 E:1350 ||| JJ
T-cell  ||| S:1350 E:1357 ||| JJ
response  ||| S:1357 E:1366 ||| NN
was  ||| S:1366 E:1370 ||| VBD
detected  ||| S:1370 E:1379 ||| VBN
as  ||| S:1379 E:1382 ||| IN
well  ||| S:1382 E:1387 ||| RB
as  ||| S:1387 E:1390 ||| IN
clinical  ||| S:1390 E:1399 ||| JJ
response  ||| S:1399 E:1408 ||| NN
to  ||| S:1408 E:1411 ||| TO
Lovaxin-C ||| S:1411 E:1420 ||| JJ
.  ||| S:1420 E:1422 ||| .
Several  ||| S:1422 E:1430 ||| JJ
other  ||| S:1430 E:1436 ||| JJ
therapeutic  ||| S:1436 E:1448 ||| JJ
HPV  ||| S:1448 E:1452 ||| NN
vaccines  ||| S:1452 E:1461 ||| NNS
are  ||| S:1461 E:1465 ||| VBP
in  ||| S:1465 E:1468 ||| IN
clinical  ||| S:1468 E:1477 ||| JJ
development  ||| S:1477 E:1489 ||| NN
and  ||| S:1489 E:1493 ||| CC
in  ||| S:1493 E:1496 ||| IN
most  ||| S:1496 E:1501 ||| JJS
of  ||| S:1501 E:1504 ||| IN
the  ||| S:1504 E:1508 ||| DT
studies  ||| S:1508 E:1516 ||| NNS
specific  ||| S:1516 E:1525 ||| JJ
immunological  ||| S:1525 E:1539 ||| NN
and  ||| S:1539 E:1543 ||| CC
clinical  ||| S:1543 E:1552 ||| JJ
responses  ||| S:1552 E:1562 ||| NNS
were  ||| S:1562 E:1567 ||| VBD
seen ||| S:1567 E:1571 ||| VBN
.  ||| S:1571 E:1573 ||| .
Efficacious  ||| S:1573 E:1585 ||| JJ
therapeutic  ||| S:1585 E:1597 ||| JJ
vaccine  ||| S:1597 E:1605 ||| NN
for  ||| S:1605 E:1609 ||| IN
the  ||| S:1609 E:1613 ||| DT
treatment  ||| S:1613 E:1623 ||| NN
of  ||| S:1623 E:1626 ||| IN
cervical  ||| S:1626 E:1635 ||| JJ
cancer  ||| S:1635 E:1642 ||| NN
should  ||| S:1642 E:1649 ||| MD
be  ||| S:1649 E:1652 ||| VB
expected  ||| S:1652 E:1661 ||| VBN
in  ||| S:1661 E:1664 ||| IN
the  ||| S:1664 E:1668 ||| DT
near  ||| S:1668 E:1673 ||| JJ
future ||| S:1673 E:1679 ||| NN
.  ||| S:1679 E:1681 ||| .
